Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease

NCT01126099 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: Prazosin
DRUG: Placebo

Sponsor

Seattle Institute for Biomedical and Clinical Research

Collaborators

[object Object]
[object Object]